Skip to main content

Table 1 Summary of seroconversion rates and T cell responses amongst patients with cancer and healthy adults

From: Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)

 

Seroconversion post 1 dose

Seroconversion post 2 doses

T cell response

Modifying factors

Solid organ cancer patients

38–83% [22, 24, 49, 50]

84–98% [20, 21, 24, 25, 49]

71% [24]

Use of steroids [24]

Combined chemoimmunotherapy [23, 24]

Haematological malignancies

18–72% [24, 49, 51]

60–85% [20, 21, 24, 25, 27, 49]

50% [24]

Anti CD20 treatment [25]

Stem cell transplant [25]

BCMA targeted therapy [27]

Anti CD38 regimens [27]

Disease response [51]

Healthy adults

100% [28, 52]

100% [28, 52]

94% [28]

Age [28]

  1. Detectable anti-Spike antibodies
  2. BCMA B cell maturation antigen